The COO of Seattle Genetics is Exercising Options

Yesterday, the COO of Seattle Genetics, Eric Dobmeier, exercised options of Seattle Genetics for $2.04M. Following Eric Dobmeier’s last SGEN Sell transaction on September 05, 2017, the stock climbed by 7.4%. In More »

A Director at Ligand Pharma is Exercising Options

Yesterday, a Director at Ligand Pharma, John Lamattina, exercised options of Ligand Pharma for $559.2K. Following John Lamattina’s last LGND Sell transaction on March 20, 2014, the stock climbed by 64.7%. In More »